Department of Pharmaceutical Biochemistry and Molecular Diagnostics, Medical University of Lodz, Lodz, Poland.
Department of Thoracic Surgery, Memorial Copernicus Hospital, Medical University of Lodz, Lodz, Poland.
Mol Genet Genomics. 2022 Nov;297(6):1505-1514. doi: 10.1007/s00438-022-01936-9. Epub 2022 Aug 10.
The study aimed to assess the HMGA1 gene expression level in NSCLC patients and to evaluate its association with selected clinicopathological features and overall survival of patients. The expression of the HMGA1, coding non-histone transcription regulator HMGA1, was previously proved to correlate with the ability of cancer cells to metastasize the advancement of the disease. The prognostic value of the HMGA1 expression level was demonstrated in some neoplasms, e.g., pancreatic, gastric, endometrial, hepatocellular cancer, but the knowledge about its role in non-small cell lung cancer (NSCLC) is still limited. Thus, the HMGA1 expression level was evaluated by real-time PCR method in postoperative tumor tissue and blood samples collected at the time of diagnosis, 100 days and 1 year after surgery from 47 NSCLC patients. Mean HMGA1 expression level in blood decreased systematically from the time of cancer diagnosis to 1 year after surgery. The blood HMGA1 expression level 1 year after surgery was associated with the tobacco smoking status of patients (p= 0.0230). Patients with high blood HMGA1 expression levels measured 100 days after surgery tend to have worse overall survival than those with low expression levels (p= 0.1197). Tumor HMGA1 expression level was associated with neither features nor the overall survival of NSCLC patients. Moreover, no correlation between HMGA1 expression level measured in tumor tissue and blood samples was stated. Blood HMGA1 mRNA level could be a promising factor in the prognostication of non-small cell lung cancer patients.
本研究旨在评估非小细胞肺癌（NSCLC）患者中 HMGA1 基因的表达水平，并评估其与选定的临床病理特征和患者总生存的关系。先前已经证明，HMGA1 基因的表达与癌细胞转移和疾病进展的能力相关，HMGA1 是一种非组蛋白转录调节因子。HMGA1 表达水平在一些肿瘤中的预后价值已经得到证实，例如胰腺癌、胃癌、子宫内膜癌和肝细胞癌，但关于其在非小细胞肺癌（NSCLC）中的作用的知识仍然有限。因此，通过实时 PCR 方法评估了 47 例 NSCLC 患者手术后肿瘤组织和诊断时、手术后 100 天和 1 年采集的血液样本中的 HMGA1 表达水平。从癌症诊断到手术后 1 年，血液中 HMGA1 的平均表达水平呈系统下降。手术后 1 年的血液 HMGA1 表达水平与患者的吸烟状况有关（p=0.0230）。手术后 100 天血液 HMGA1 表达水平较高的患者总生存时间可能比表达水平较低的患者差（p=0.1197）。肿瘤 HMGA1 表达水平与 NSCLC 患者的特征或总生存无关。此外，肿瘤组织和血液样本中测量的 HMGA1 表达水平之间没有相关性。血液 HMGA1 mRNA 水平可能是预测非小细胞肺癌患者预后的有前途的因素。
